359 related articles for article (PubMed ID: 27862622)
1. Metabolic tumor volume provides complementary prognostic information to EUS staging in esophageal and junctional cancer.
Malik V; Johnston C; O'Toole D; Lucey J; O'Farrell N; Claxton Z; Reynolds JV
Dis Esophagus; 2017 Feb; 30(3):1-8. PubMed ID: 27862622
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.
Hyun SH; Choi JY; Shim YM; Kim K; Lee SJ; Cho YS; Lee JY; Lee KH; Kim BT
Ann Surg Oncol; 2010 Jan; 17(1):115-22. PubMed ID: 19826877
[TBL] [Abstract][Full Text] [Related]
3. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma.
Hofheinz F; Li Y; Steffen IG; Lin Q; Lili C; Hua W; van den Hoff J; Zschaeck S
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1485-1494. PubMed ID: 30949816
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
5. N-staging of oesophageal and junctional carcinoma: is there still a role for EUS in patients staged N0 at PET/CT?
Foley KG; Lewis WG; Fielding P; Karran A; Chan D; Blake P; Roberts SA
Clin Radiol; 2014 Sep; 69(9):959-64. PubMed ID: 24916652
[TBL] [Abstract][Full Text] [Related]
6.
Mantziari S; Pomoni A; Prior JO; Winiker M; Allemann P; Demartines N; Schäfer M
BMC Med Imaging; 2020 Jan; 20(1):7. PubMed ID: 31969127
[TBL] [Abstract][Full Text] [Related]
7. Texture analysis of
Nakajo M; Jinguji M; Nakabeppu Y; Nakajo M; Higashi R; Fukukura Y; Sasaki K; Uchikado Y; Natsugoe S; Yoshiura T
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):206-214. PubMed ID: 27613542
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of 18-FDG PET/CT and EUS-defined tumour characteristics in patients with oesophageal cancer.
Chan DS; Fielding P; Roberts SA; Reid TD; Ellis-Owen R; Lewis WG
Clin Radiol; 2013 Apr; 68(4):352-7. PubMed ID: 22981727
[TBL] [Abstract][Full Text] [Related]
9. The predictive recurrence value of MTV-s as an 18F-FDG PET/CT index in patients with IIB-IVA cervical cancer.
Deng C; Ding D; Wang M
Postgrad Med; 2021 May; 133(4):436-443. PubMed ID: 33620285
[No Abstract] [Full Text] [Related]
10. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer.
Omloo JM; Sloof GW; Boellaard R; Hoekstra OS; Jager PL; van Dullemen HM; Fockens P; Plukker JT; van Lanschot JJ
Endoscopy; 2008 Jun; 40(6):464-71. PubMed ID: 18543134
[TBL] [Abstract][Full Text] [Related]
11. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of volume-based 18F-FDG PET/CT parameter in patients with surgically resected non-small cell lung cancer. Comparison with immunohistochemical biomarkers.
Lee JY; Choi JY; Heo JH; Han J; Jang SJ; Kim K; Kim J; Shim YM; Kim BT
Nuklearmedizin; 2016; 55(1):7-14. PubMed ID: 26875430
[TBL] [Abstract][Full Text] [Related]
13.
Lehmann K; Eshmuminov D; Bauerfeind P; Gubler C; Veit-Haibach P; Weber A; Abdul-Rahman H; Fischer M; Reiner C; Schneider PM
Eur J Surg Oncol; 2017 Jan; 43(1):196-202. PubMed ID: 27692533
[TBL] [Abstract][Full Text] [Related]
14. Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation.
Li Y; Zschaeck S; Lin Q; Chen S; Chen L; Wu H
Radiat Oncol; 2019 Feb; 14(1):35. PubMed ID: 30782182
[TBL] [Abstract][Full Text] [Related]
15. A Diagnostic Algorithm That Combines Quantitative 18F-FDG PET Parameters and Contrast-Enhanced CT Improves Posttherapeutic Locoregional Restaging and Prognostication of Survival in Patients With Esophageal Cancer.
Tamandl D; Fueger B; Haug A; Schmid R; Stift J; Schoppmann SF; Ilhan-Mutlu A; Ba-Ssalamah A
Clin Nucl Med; 2019 Jan; 44(1):e13-e21. PubMed ID: 30418211
[TBL] [Abstract][Full Text] [Related]
16. Appraisal of staging endoscopic ultrasonography in a modern high-volume esophageal program.
O'Farrell NJ; Malik V; Donohoe CL; Johnston C; Muldoon C; Reynolds JV; O'Toole D
World J Surg; 2013 Jul; 37(7):1666-72. PubMed ID: 23568244
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
18. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
[TBL] [Abstract][Full Text] [Related]
19. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters.
Chang S; Kim SJ
Cancer Biother Radiopharm; 2016 Feb; 31(1):1-6. PubMed ID: 26844846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
